Progress in pancreatic cancer: moving beyond gemcitabine?

Expert Rev Anticancer Ther. 2012 Aug;12(8):997-1000. doi: 10.1586/era.12.78.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Carcinoma, Pancreatic Ductal / drug therapy*
  • Carcinoma, Pancreatic Ductal / metabolism
  • Carcinoma, Pancreatic Ductal / mortality
  • Carcinoma, Pancreatic Ductal / surgery
  • Chemotherapy, Adjuvant
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Equilibrative Nucleoside Transporter 1 / metabolism
  • Gemcitabine
  • Humans
  • Irinotecan
  • Leucovorin / administration & dosage
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / surgery

Substances

  • Equilibrative Nucleoside Transporter 1
  • Organoplatinum Compounds
  • SLC29A1 protein, human
  • Oxaliplatin
  • Deoxycytidine
  • Irinotecan
  • Leucovorin
  • Camptothecin
  • Gemcitabine